[EN] NOVEL AZAINDOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] NOUVEAUX DÉRIVÉS AZAINDOLE COMME INHIBITEURS SÉLECTIFS DE L'HISTONE DÉSACÉTYLASE (HDAC) ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
申请人:CHONG KUN DANG PHARM CORP
公开号:WO2015087151A1
公开(公告)日:2015-06-18
The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.
本发明涉及新型的吖吲哚衍生物,特别是具有组蛋白去乙酰化酶(HDAC)抑制活性的新型吖吲哚衍生物,其异构体,药用可接受的盐,水合物或溶剂化物,以及它们用于制备药物组合物的用途,包含同一的药物组合物,使用该药物组合物治疗疾病的方法,以及制备新型吖吲哚衍生物的方法。根据本发明的吖吲哚衍生物是选择性的组蛋白去乙酰化酶(HDAC)抑制剂,可用作治疗恶性肿瘤疾病,炎症性疾病,类风湿性关节炎和神经退行性疾病的治疗剂。